SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AVIGEN(avgn)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: stock talk who wrote (3)1/8/1997 7:37:00 AM
From: Tom M   of 228
 
All: Here are a few encouraging recent news brief headlines.
It may give you a feel for the kind of things they're into.
As w/most new IPO stocks, investors are waiting for it to prove itself before they buy in. One publicized breakthrough & zoom. With a current ~$5 entry fee, I don't know how low it has to go for the masses to deem it a good risk. It's Tucker Anthony's Bio-tech analyst's top pick for potential.

11/26/96 08:14 Avigen Demonstrates Gene Delivery Success With Erythropoietin [PR Newswire, 715 words]

11/11/96 16:31 Avigen and Johns Hopkins Scientists Report Gene Therapy Progress in Treating Heart Disease at American Heart Association Meeting [PR Newswire, 627 words]

11/07/96 18:46 Avigens (NASDAQ:AVGN) tumor therapy effective in tests [Reuters, 156 words]

11/07/96 08:15 Avigen Reports Success in Treating Brain Tumors [PR Newswire, 739 words]

10/21/96 12:49 Initiating coverage of Avigen Inc., Wedbush Morgan rates its stock a ``Buy'' [BusinessWire, 440 words]

tom
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext